Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $169.1 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 5.08% year-over-year to $169.1 million in Q1 2026; TTM through Mar 2026 was $169.1 million, a 5.08% increase from a year earlier, with the FY2025 full-year figure at $186.8 million, up 17.36% from the prior year.
• Total Non-Current Liabilities retreated to $169.1 million in Q1 2026 per AQST's latest filing, from $186.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $186.8 million in Q4 2025 and bottomed at $147.8 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $161.6 million (2023), against an average of $162.1 million.
• Across the five-year window, Total Non-Current Liabilities jumped 32.02% in 2022 and fell 6.74% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $173.6 million in 2022, then dropped by 6.74% to $161.9 million in 2023, then dropped by 1.67% to $159.2 million in 2024, then grew by 17.36% to $186.8 million in 2025, then dropped by 9.47% to $169.1 million in 2026.
• Per Business Quant, the three latest AQST Total Non-Current Liabilities figures stand at $169.1 million (Q1 2026), $186.8 million (Q4 2025), and $165.6 million (Q3 2025).